Dr Helen Tayton Martin | Chief Business Officer
Adaptimmune Llc

Dr Helen Tayton Martin, Chief Business Officer, Adaptimmune Llc

Dr. Helen Tayton‑Martin has served as Adaptimmune’s Chief Operating Officer since July 2008 and is one of its co-founders. She is responsible for business development and commercial activities, including our strategic partnership with GSK. Dr. Tayton-Martin has 23 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She is a co-founder of Adaptimmune, joining from Avidex Limited (subsequently Medigene) where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy from 2005 to 2008. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.


Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 14:30

Panel Discussion: How can clinical challenges be overcome to enable CAR-T and immunotherapy to help more patients?

Advanced Therapies and Regenerative Medicine Day 1 - Wednesday 16th May 2018 @ 17:05

Dissecting the latest clinical data and commercial business models for leading European and US CAR-T cell and TCR therapy developers

back to speakers

World Advanced Therapies & Regenerative Medicine Congress


Erica Baeta
+44 (0)207 092 1152


Jessica Robinson
t/ +44 (0)207 092 1150


Issa Mauthoor
+44 (0)207 092 1257